A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases
B Booth(United States Food and Drug Administration), Jogarao Gobburu(University of Maryland, Baltimore), Horst Schran(Novartis (Switzerland)), Peiming Ma(GlaxoSmithKline (China)), Amna Ibrahim(Beni-Suef University), Atiqur Rahman(Jamia Millia Islamia), C. Hsu(Novartis (Switzerland)), G.C. Williams(Novartis (Switzerland)), Nancy S. Scher
Cited by 3
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
United States Food and Drug Administration Drug Approval Summary
|Clinical Cancer Research|2004|500